ASC30 vs regor GLP-1
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1 receptor · full Obesity pipeline
ASC30
Developed by Ascletis Pharma
NCT07002905 · Phase 2 · completed
The study randomly assigned 125 participants and used quadruple blinding with placebo control across seven cohorts. Its primary endpoint was percent change in body weight at Week 13, but the registry has not posted whether this endpoint was met.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: July 2028 · NCT07743463 (registry estimate)
Reported efficacy
Percent change in body weight from Baseline up to Week 13 (Baseline and Week 13): Placebo-adjusted mean weight loss at Week 13: 5.4% (20mg), 7.0% (40mg), 7.7% (60mg) ASC30, all p<0.0001 vs placebo (met)
Result source: NCT07002905
regor GLP-1
Developed by Regor Pharmaceuticals
NCT06867718 · Phase 2 · completed
The trial randomized 267 participants to four active-dose groups or placebo and masked both participants and investigators. Its primary endpoint was percent change in body weight at Week 36, but the registry does not report whether the comparison met its statistical objective, so the evidence is currently limited to a well-controlled study design with an unknown result.
Reported efficacy
Number of participants with Treatment-emergent Adverse Event(AE) by severity/Serious Adverse Event (SAE), with Clinical Laboratory Abnormalities, Clinically Significant Change From Baseline in Vital Signs and Abnormal Electrocardiogram(ECG) readings (14 weeks): Safety (this trial's registered primary endpoint): AE-related discontinuation 4%, identical in drug and placebo arms; no treatment-related severe/serious AEs; nausea in 40% and vomiting in 24% of the RGT-075 arm; 1 patient (2%) required dose reduction. (not_applicable)
Result source: NCT06277934
Results for Obesity
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.
| Key endpoint | ASC30 | regor GLP-1 |
|---|---|---|
| Body weight, % change | —Trial running · NCT07743463 | —Not reported |
| Weight loss of 5% or more | —Trial running · NCT07743463 | —Not reported |
| Weight loss of 10% or more | —Trial running · NCT07743463 | —Not reported |
| Waist circumference, change (cm) | —Trial running · NCT07743463 | —Not reported |
Body weight, % change
- ASC30
- —Trial running · NCT07743463
- regor GLP-1
- —Not reported
Weight loss of 5% or more
- ASC30
- —Trial running · NCT07743463
- regor GLP-1
- —Not reported
Weight loss of 10% or more
- ASC30
- —Trial running · NCT07743463
- regor GLP-1
- —Not reported
Waist circumference, change (cm)
- ASC30
- —Trial running · NCT07743463
- regor GLP-1
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
ASC30
show 2 more results
regor GLP-1
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ASC30's landscape · regor GLP-1's landscape